IDH1 and acute myeloid leukemia: Several other IDH mutation inhibitor candidates have shown promising efficacy in preclinical studies and AML clinical trials, including MRK-A [146], FT-2102 (Olutasidenib) [147], HMS-101 [148], and IDH305 [149] (a summary of IDH mutation inhibitors is available in Table 2).